Health care utilization by men with prostate cancer during the year before their death: A 2015 population-based study.

Cancer de la prostate Costs Coûts End of life Fin de vie Health care utilization Lieu de décès Place of death Prostate cancer Recours aux soins

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 12 06 2019
revised: 27 09 2019
accepted: 28 09 2019
pubmed: 12 11 2019
medline: 27 3 2020
entrez: 12 11 2019
Statut: ppublish

Résumé

To study the characteristics and health care utilization of men with prostate cancer (PCa) during their last year and last month of life, as these data have been rarely reported to date. Men covered by the national health Insurance general scheme (77% of the French population) treated for PCa (2014-2015), who died in 2015 were identified in the national health data system, including reimbursed hospital and outpatient care, and their causes of death. A total of 11,193 men (mean age: 81 years, SD: 9.6) were included. Almost 58% of these men died in a short-stay hospital (SSH), 4% died in hospital-at-home, 9% died in Rehab, 9% died in skilled nursing homes and 21% died at home. During the last year of life, almost all men were hospitalised at least once in SSH and 47% received hospital palliative care (HPC), immediately prior to death in 8% of cases. During the last month of life, 76% of men were hospitalised at least once in SSH, 43% attended an emergency department and 14% were admitted to intensive care, 7% received a chemotherapy session, and 24% received an antineoplastic agent dispensed by a retail pharmacy. Cancer was the main cause of death for 63% of men, corresponding to PCa in 40% of cases, and cardiovascular disease was the main cause of death for 13% of men with marked variations according to age, place of death, and use of HPC. The mean cost reimbursed per man during the last year of life was €38,750 (€48,601 including HPC). In France, end-of-life management of men with PCa, regardless of the cause of death, is centered on SSH and HPC, essentially at the time of death. Certain indicators of end-of-life management were particular high. 4.

Identifiants

pubmed: 31708329
pii: S1166-7087(19)30540-8
doi: 10.1016/j.purol.2019.09.006
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

995-1006

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

A Tanguy-Melac (A)

Caisse nationale de l'assurance maladie (Cnam), Paris, France.

T Lesuffleur (T)

Caisse nationale de l'assurance maladie (Cnam), Paris, France.

A Fagot-Campagna (A)

Caisse nationale de l'assurance maladie (Cnam), Paris, France.

C Gastaldi-Ménager (C)

Caisse nationale de l'assurance maladie (Cnam), Paris, France.

X Rébillard (X)

EA2415, service d'urologie, clinique Beau Soleil, Montpellier, France.

P Tuppin (P)

Caisse nationale de l'assurance maladie (Cnam), Paris, France. Electronic address: philippe.tuppin@cnamts.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH